Denali Therapeutics Reports $126.9 Million Net Loss in Q3 2025, Increases R&D Investments

Denali Therapeutics Inc. reported a net loss of $126.9 million for the third quarter of 2025, compared to a net loss of $107.2 million for the same period in 2024, marking an 18% increase in losses year-over-year. For the nine months ended September 30, 2025, the company recorded a net loss of $384.0 million, up from $308.0 million in the prior year. Total operating expenses for the third quarter were $137.4 million, a 12% increase from $123.2 million in the same quarter of the previous year, driven primarily by higher general and administrative costs, which rose by 42% to $35.5 million.

The company's financial position showed a significant decrease in cash and cash equivalents, which fell to $90.9 million as of September 30, 2025, down from $175.0 million at the end of 2024. However, total current assets increased slightly to $882.6 million, primarily due to an increase in short-term marketable securities, which rose to $757.2 million from $657.4 million. Denali's accumulated deficit also widened to $1.92 billion, reflecting ongoing investments in research and development.

In terms of strategic developments, Denali has been actively advancing its clinical programs, including the submission of a Biologics License Application (BLA) for tividenofusp alfa (DNL310) for the treatment of MPS II, which has received Breakthrough Therapy Designation from the FDA. The company also announced plans for a global Phase 3 study for DNL126, aimed at treating Sanfilippo syndrome, and has expanded its manufacturing capabilities with a new facility in Salt Lake City, Utah. These initiatives are part of Denali's strategy to develop a new class of therapeutics targeting neurodegenerative diseases.

Operationally, Denali's research and development expenses increased to $101.9 million for the third quarter of 2025, up from $98.2 million in the same quarter of 2024. This increase was attributed to higher costs associated with external research and development activities and personnel-related expenses, reflecting the company's growing workforce and operational scale. The company also reported a decrease in expenses related to small molecule programs, which have been winding down as part of its strategic focus.

Looking ahead, Denali anticipates continued operating losses as it invests in the development of its product candidates and prepares for potential commercialization. The company expects to require substantial additional funding to support its operations and meet future commitments. As of September 30, 2025, Denali had cash, cash equivalents, and marketable securities totaling $872.9 million, which it believes will be sufficient to fund operations for at least the next twelve months. However, the company acknowledges the inherent risks and uncertainties in drug development, which could impact its financial outlook and operational plans.